Literature DB >> 8096068

Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.

J Embretson1, M Zupancic, J L Ribas, A Burke, P Racz, K Tenner-Racz, A T Haase.   

Abstract

Animal and human lentiviruses elude host defences by establishing covert infections and eventually cause disease through cumulative losses of cells that die with activation of viral gene expression. We used polymerase chain reaction in situ double-label methods to determine how many CD4+ lymphocytes are latently infected by human immunodeficiency virus (HIV) in patient lymph nodes and whether the pool of infected cells is large enough to account for immune depletion through continual activation of viral gene expression and attrition of cells responding to antigens. We discovered an extraordinarily large number of latently infected CD4+ lymphocytes and macrophages throughout the lymphoid system from early to late stages of infection, and confirmed the extracellular association of HIV with follicular dendritic cells. Follicular dendritic cells may transmit infection to cells as they migrate through lymphoid follicles. Latently infected lymphocytes and macrophages constitute an intracellular reservoir large enough ultimately to contribute to much of the immune depletion in AIDS, and represent a difficult problem that must be resolved in developing effective treatments and protective vaccine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096068     DOI: 10.1038/362359a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  377 in total

1.  T-cell induced pathogenesis in HIV: bystander effects and latent infection.

Authors:  D C Krakauer; M Nowak
Journal:  Proc Biol Sci       Date:  1999-05-22       Impact factor: 5.349

2.  Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.

Authors:  G P Rizzardi; R J De Boer; S Hoover; G Tambussi; A Chapuis; N Halkic; P A Bart; V Miller; S Staszewski; D W Notermans; L Perrin; C H Fox; J M Lange; A Lazzarin; G Pantaleo
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

3.  Benchmarks for antiretroviral therapy.

Authors:  O J Cohen; A S Fauci
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

4.  HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death.

Authors:  S J Brodie; B K Patterson; D A Lewinsohn; K Diem; D Spach; P D Greenberg; S R Riddell; L Corey
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

5.  Reservoirs for HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

6.  An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus.

Authors:  S Gummuluru; C M Kinsey; M Emerman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 7.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

8.  Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL.

Authors:  Elizabeth Connick; Joy M Folkvord; Katherine T Lind; Eva G Rakasz; Brodie Miles; Nancy A Wilson; Mario L Santiago; Kimberly Schmitt; Edward B Stephens; Hyeon O Kim; Reece Wagstaff; Shengbin Li; Hadia M Abdelaal; Nathan Kemp; David I Watkins; Samantha MaWhinney; Pamela J Skinner
Journal:  J Immunol       Date:  2014-10-31       Impact factor: 5.422

9.  Monocytes are required to prime peripheral blood T cells to undergo apoptosis.

Authors:  M X Wu; J F Daley; R A Rasmussen; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

10.  Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.

Authors:  F Re; D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.